In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.
作者信息
Sierra J M, Ruiz J, Navia M M, Vargas M, Vila J
出版信息
Antimicrob Agents Chemother. 2001 Feb;45(2):643--4. doi: 10.1128/AAC.45.2.643-644.2001.
Abstract
摘要
相似文献
1
In vitro activity of rifaximin against enteropathogens producing traveler's diarrhea.利福昔明对导致旅行者腹泻的肠道病原体的体外活性。
Antimicrob Agents Chemother. 2001 Feb;45(2):643--4. doi: 10.1128/AAC.45.2.643-644.2001.
2
In vitro antimicrobial activity of rifaximin against enteropathogens causing traveler's diarrhea.利福昔明对引起旅行者腹泻的肠道病原体的体外抗菌活性。
Diagn Microbiol Infect Dis. 2007 Dec;59(4):473-5. doi: 10.1016/j.diagmicrobio.2007.07.003. Epub 2007 Sep 21.
3
In vitro activity of rifaximin against bacterial enteropathogens causing diarrhoea in children under 5 years of age in Ifakara, Tanzania.利福昔明对坦桑尼亚伊法卡拉5岁以下儿童细菌性腹泻病原体的体外活性
J Antimicrob Chemother. 2001 Jun;47(6):904-5. doi: 10.1093/jac/47.6.904.
4
In vitro activity and fecal concentration of rifaximin after oral administration.口服后利福昔明的体外活性及粪便浓度
Antimicrob Agents Chemother. 2000 Aug;44(8):2205-6. doi: 10.1128/AAC.44.8.2205-2206.2000.
5
In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.利福昔明对从返回英国的旅行者中分离出的临床大肠杆菌和其他肠致病性细菌的体外活性。
Int J Antimicrob Agents. 2014 May;43(5):431-7. doi: 10.1016/j.ijantimicag.2014.01.026. Epub 2014 Mar 1.
6
In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler's diarrhea in four geographic regions.四个地理区域中引起旅行者腹泻的细菌性肠道病原体的体外抗菌药敏试验。
Antimicrob Agents Chemother. 2001 Jan;45(1):212-6. doi: 10.1128/AAC.45.1.212-216.2001.
7
Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders.利福昔明：一种用于胃肠道疾病的新型非吸收性利福霉素。
Clin Infect Dis. 2006 Feb 15;42(4):541-7. doi: 10.1086/499950. Epub 2006 Jan 17.
8
Treatment of travelers' diarrhea.旅行者腹泻的治疗
J Travel Med. 2001 Dec;8(Suppl 2):S31-3. doi: 10.1111/j.1708-8305.2001.tb00544.x.
9
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.检测 rifamycin SV 对旅行者腹泻和艰难梭菌相关病原体的体外活性和单步突变分析。
Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.
10
Antibacterial chemoprophylaxis in the prevention of traveler's diarrhea: evaluation of poorly absorbed oral rifaximin.抗菌化学预防在预防旅行者腹泻中的应用：对吸收不良的口服利福昔明的评估
Clin Infect Dis. 2005 Dec 1;41 Suppl 8:S571-6. doi: 10.1086/432954.
引用本文的文献
1
Challenges in the Investigation of Therapeutic Equivalence of Locally Applied/Locally Acting Drugs in the Gastrointestinal Tract: The Rifaximin Case.胃肠道局部应用/局部作用药物治疗等效性研究中的挑战：利福昔明案例
Pharmaceutics. 2025 Jun 27;17(7):839. doi: 10.3390/pharmaceutics17070839.
2
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.利福昔明-α相关的临床微生物耐药性的发展潜力：叙事性综述。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0003923. doi: 10.1128/cmr.00039-23. Epub 2023 Nov 16.
3
Diverticular Disease and Rifaximin: An Evidence-Based Review.憩室病与利福昔明：一项基于证据的综述。
Antibiotics (Basel). 2023 Feb 23;12(3):443. doi: 10.3390/antibiotics12030443.
4
Emergence of Resistance to Quinolones and β-Lactam Antibiotics in Enteroaggregative and Enterotoxigenic Causing Traveler's Diarrhea.肠聚集性和肠毒性导致旅行者腹泻的耐喹诺酮类和β-内酰胺类抗生素的出现。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01745-18. Print 2019 Feb.
5
Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.旅行者腹泻防治指南：一份分级专家小组报告。
J Travel Med. 2017 Apr 1;24(suppl_1):S57-S74. doi: 10.1093/jtm/tax026.
6
Rifaximin therapy of irritable bowel syndrome.利福昔明治疗肠易激综合征
Clin Med Insights Gastroenterol. 2012 Jun 25;5:31-41. doi: 10.4137/CGast.S7382. eCollection 2012.
7
Emerging Aeromonas species infections and their significance in public health.新出现的气单胞菌属物种感染及其在公共卫生中的意义。
ScientificWorldJournal. 2012;2012:625023. doi: 10.1100/2012/625023. Epub 2012 Jun 4.
8
Rifaximin for the treatment of acute infectious diarrhea.利福昔明治疗急性感染性腹泻。
Therap Adv Gastroenterol. 2011 Jul;4(4):227-35. doi: 10.1177/1756283X11398734.
9
Bile acids improve the antimicrobial effect of rifaximin.胆汁酸可增强利福昔明的抗菌作用。
Antimicrob Agents Chemother. 2010 Sep;54(9):3618-24. doi: 10.1128/AAC.00161-10. Epub 2010 Jun 14.
10
The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea.利福昔明在旅行者腹泻治疗和化学预防中的作用。
Ther Clin Risk Manag. 2009;5:841-8. doi: 10.2147/tcrm.s4442. Epub 2009 Nov 2.
本文引用的文献
1
In vitro activity and fecal concentration of rifaximin after oral administration.口服后利福昔明的体外活性及粪便浓度
Antimicrob Agents Chemother. 2000 Aug;44(8):2205-6. doi: 10.1128/AAC.44.8.2205-2206.2000.
2
Tropical and exotic infections. Proceedings of the 5th Liverpool Tropical School Bayer Symposium on Microbial Diseases. 14 February 1998.热带和外来感染。第五届利物浦热带医学院拜耳微生物疾病研讨会会议记录。1998年2月14日。
J Med Microbiol. 2000 Jan;49(1):5-27. doi: 10.1099/0022-1317-49-1-5.
3
Antimicrobial resistance of diarrheagenic Escherichia coli isolated from children under the age of 5 years from Ifakara, Tanzania.从坦桑尼亚伊法卡拉5岁以下儿童中分离出的致泻性大肠杆菌的抗菌耐药性
Antimicrob Agents Chemother. 1999 Dec;43(12):3022-4. doi: 10.1128/AAC.43.12.3022.
4
The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.环丙沙星耐药的全球流行病学及抗生素耐药性的变化本质：十年视角
J Antimicrob Chemother. 1999 Mar;43 Suppl A:31-40. doi: 10.1093/jac/43.suppl_1.31.
5
Antimicrobial Resistance of Nontyphoidal Salmonella Isolates in Traveler's Diarrhea.旅行者腹泻中非伤寒沙门氏菌分离株的抗菌药物耐药性
J Travel Med. 1995 Mar 1;2(1):45-47. doi: 10.1111/j.1708-8305.1995.tb00620.x.
6
Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea.利福昔明：一种用于治疗旅行者腹泻的不被吸收的抗菌药物。
Digestion. 1998 Nov-Dec;59(6):708-14. doi: 10.1159/000007580.
7
Campylobacter jejuni as a cause of traveler's diarrhea: clinical features and antimicrobial susceptibility.空肠弯曲菌作为旅行者腹泻的病因：临床特征及抗菌药物敏感性
J Travel Med. 1998 Mar;5(1):23-6. doi: 10.1111/j.1708-8305.1998.tb00451.x.
8
Etiology of traveller's diarrhea in Spanish travellers to developing countries.前往发展中国家的西班牙旅行者发生旅行者腹泻的病因
Eur J Epidemiol. 1993 Mar;9(2):217-23. doi: 10.1007/BF00158796.
9
Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative.新型局部用利福霉素衍生物利福昔明的抗菌活性及抗菌谱
Diagn Microbiol Infect Dis. 1993 Feb;16(2):111-8. doi: 10.1016/0732-8893(93)90004-q.
10
Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria.利福昔明。对其抗菌活性、药代动力学特性及在胃肠道细菌介导疾病中的治疗潜力的综述。
Drugs. 1995 Mar;49(3):467-84. doi: 10.2165/00003495-199549030-00009.
Zotero 插件